FAITH will have trial sites in three hospitals:


Champalimaud in Lisbon, Portugal


HGUGM in Madrid, Spain


UPMC in Waterford, Ireland


The hospitals will carry out trial pilots involving real end users (both clinicians and patients) to assess the usability and feasibility of the FAITH concept.
After an initial requirements gathering, the concept will be prototyped for a real-life situation trial to use at the hospital pilot sites. The trials, specifically related to each use case, will allow FAITH to be validated by doctors and patients according to their specific needs.
Results and findings from pilots’ execution will be used as feedback and input for a further round of requirements gathering and concept refinement.

All pilots will be subject to the highest ethical standards to assure the privacy and protection of data.

IMPLEMENTATION PHASES

PILOTS TRIAL SITES

Champalimaud Centre for the Unknown | Lisbon, Portugal

Since 2010, the Champalimaud Centre for the Unknown (CCU) has been a state-of-the-art centre for research, diagnosis and treatment of cancer in Portugal. It houses the Champalimaud Clinical Centre (CCC), whose multidisciplinary teams focus their activity on the patient, offering care of excellence based on the most advanced technological means. Since its creation, the CCC has been involved in over 60 clinical studies, with a focus on clinical research and practice in cancer, systems pathology and neuropsychiatry.

Users

As a clinical partner, the Champalimaud Clinical Centre will involve 100 ambulatory, community dwelling, lung-cancer patients (of any type) with indication for oncological treatment over two years. All patients will receive psychological and cognitive assessments through psychosocial questionnaires, neuropsychological testing, and other constructs. The CCC will monitor them for 12 months after their first appointment, offering them intelligent post-cancer support.

Hospital G.U. Gregorio Marañón | Madrid, Spain

The Hospital General Universitario Gregorio Marañón (HGUGM) is part of the Servicio Madrileño de Salud, which manages and provides health services in the Public National Health Care system in the Region of Madrid. HGUGM comprises more than 20 buildings and employs over 7,500 professionals. The HGUGM provides direct healthcare to 450,000 citizens, and is the referral center for high-tech care at a national level. Its Medical Oncology Service, composed by a multidisciplinary team of professionals, delivers comprehensive and individualized care to patients with different oncological pathologies, providing access to the most effective oncological treatments available on the market, as well as novel drugs in the process of development through participation in clinical trials.

Users

The pilot study will comprise 100 patients that are survival of breast cancer. They will be monitored to evaluate their quality of life and highlight possible aftercare needs, in order to provide better, personalized interventions.
The information obtained will allow doctors and healthcare professionals to detect different disorders that would help to design protocols and standards of care for an early intervention, improving patient’s quality of life.

UPMC | Waterford, Ireland

A $21 billion healthcare provider and insurer, Pittsburgh, Pennsylvania-based UPMC is inventing new models of patient-centred, cost-effective, accountable care. Working in close collaboration with the University of Pittsburgh Schools of the Health Sciences, UPMC shares its clinical, managerial and technological skills worldwide.
Providing high-quality healthcare in South East Ireland since 2006, UPMC’s operations in Ireland now include UPMC Whitfield Hospital in Waterford, UPMC Kildare Hospital in Clane, the UPMC Carlow Outreach Centre, UPMC Hillman Cancer Centre radiotherapy locations at UPMC Whitfield and in Cork, and the UPMC Concussion Network. UPMC is the Official Healthcare Partner of the GAA and GPA.

Users

UPMC will be the main Irish pilot test trial site, focusing on breast cancer patients as the selected use case and target group for FAITH. UPMC recognizes that caring for the wellbeing and mental health of patients on treatment – and of those who have completed treatment – is just important as providing advanced, high-quality clinical care. Combined with offering the most advanced oncology care to patients close to home, UPMC’s team of oncologists intends to offer the FAITH tool to patients to identify patients who would benefit from follow up care with their oncologist, GP, or referral to their local Cancer Support Centre.

FAITH will have trial sites in three hospitals:


Champalimaud in Lisbon, Portugal


HGUGM in Madrid, Spain


UPMC in Waterford, Ireland


The hospitals will carry out trial pilots involving real end users (both clinicians and patients) to assess the usability and feasibility of the FAITH concept.
After an initial requirements gathering, the concept will be prototyped for a real-life situation trial to use at the hospital pilot sites. The trials, specifically related to each use case, will allow FAITH to be validated by doctors and patients according to their specific needs.
Results and findings from pilots’ execution will be used as feedback and input for a further round of requirements gathering and concept refinement.

All pilots will be subject to the highest ethical standards to assure the privacy and protection of data.

IMPLEMENTATION PHASES

PILOTS TRIAL SITES

Champalimaud Centre for the Unknown | Lisbon, Portugal

Since 2010, the Champalimaud Centre for the Unknown (CCU) has been a state-of-the-art centre for research, diagnosis and treatment of cancer in Portugal. It houses the Champalimaud Clinical Centre (CCC), whose multidisciplinary teams focus their activity on the patient, offering care of excellence based on the most advanced technological means. Since its creation, the CCC has been involved in over 60 clinical studies, with a focus on clinical research and practice in cancer, systems pathology and neuropsychiatry.

Users

As a clinical partner, the Champalimaud Clinical Centre will involve 100 ambulatory, community dwelling, lung-cancer patients (of any type) with indication for oncological treatment over two years. All patients will receive psychological and cognitive assessments through psychosocial questionnaires, neuropsychological testing, and other constructs. The CCC will monitor them for 12 months after their first appointment, offering them intelligent post-cancer support.

Hospital G.U. Gregorio Marañón | Madrid, Spain

The Hospital General Universitario Gregorio Marañón (HGUGM) is part of the Servicio Madrileño de Salud, which manages and provides health services in the Public National Health Care system in the Region of Madrid. HGUGM comprises more than 20 buildings and employs over 7,500 professionals. The HGUGM provides direct healthcare to 450,000 citizens, and is the referral center for high-tech care at a national level. Its Medical Oncology Service, composed by a multidisciplinary team of professionals, delivers comprehensive and individualized care to patients with different oncological pathologies, providing access to the most effective oncological treatments available on the market, as well as novel drugs in the process of development through participation in clinical trials.

Users

The pilot study will comprise 100 patients that are survival of breast cancer. They will be monitored to evaluate their quality of life and highlight possible aftercare needs, in order to provide better, personalized interventions.
The information obtained will allow doctors and healthcare professionals to detect different disorders that would help to design protocols and standards of care for an early intervention, improving patient’s quality of life.

UPMC | Waterford, Ireland

A $21 billion healthcare provider and insurer, Pittsburgh, Pennsylvania-based UPMC is inventing new models of patient-centred, cost-effective, accountable care. Working in close collaboration with the University of Pittsburgh Schools of the Health Sciences, UPMC shares its clinical, managerial and technological skills worldwide.
Providing high-quality healthcare in South East Ireland since 2006, UPMC’s operations in Ireland now include UPMC Whitfield Hospital in Waterford, UPMC Kildare Hospital in Clane, the UPMC Carlow Outreach Centre, UPMC Hillman Cancer Centre radiotherapy locations at UPMC Whitfield and in Cork, and the UPMC Concussion Network. UPMC is the Official Healthcare Partner of the GAA and GPA.

Users

UPMC will be the main Irish pilot test trial site, focusing on breast cancer patients as the selected use case and target group for FAITH. UPMC recognizes that caring for the wellbeing and mental health of patients on treatment – and of those who have completed treatment – is just important as providing advanced, high-quality clinical care. Combined with offering the most advanced oncology care to patients close to home, UPMC’s team of oncologists intends to offer the FAITH tool to patients to identify patients who would benefit from follow up care with their oncologist, GP, or referral to their local Cancer Support Centre.